New Approvals for Engineered T-cell Receptor Therapy for Rare Soft Tissue Cancer

Afamitresgene autoleucel was granted full approval with an expanded indication for certain adult and pediatric patients with advanced synovial sarcoma.

The U.S. Food and Drug Administration (FDA) has granted full approval to afamitresgene autoleucel (afami-cel, Tecelra) for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy. Patients must express certain genetic variants of the human leukocyte antigen A (HLA-A) gene (HLA-A02:01P, HLA-A02:02P, HLA-A02:03P, or HLA-A02:06P), and their tumor must express a protein called melanoma-associated antigen A4 (MAGE-A4) as determined by companion diagnostic devices that have also been approved or cleared by the FDA.

Afami-cel is an engineered T-cell receptor (TCR) T-cell therapy, a type of cell-based immunotherapy which works by taking a patient’s own T cells, engineering them to produce a tumor-specific TCR, and infusing them back into the patient. Specifically, afami-cel recognizes and binds to the MAGE-A4 protein when this is presented on the surface of cancer cells by specific HLA proteins. Therefore, afami-cel is approved only for patients who have such an HLA. When the T cells bind to the antigen-HLA combination, they become activated and destroy the cancer cells.

For a TCR T-cell therapy like afamitresgene autoleucel, T cells are harvested from a patient’s blood and genetically modified to carry a new T-cell receptor that enables them to recognize certain protein fragments in the patient’s cancer cells.

Afami-cel received accelerated FDA approval for certain adult patients with synovial sarcoma in 2024. The conversion to full approval also expanded its indication to include pediatric patients 12 years of age and older. Afami-cel was the first TCR T-cell therapy approved for any cancer type and the first cell-based immunotherapy approved for a solid tumor in the United States.

The full approval was based on results from the open-label, single-arm phase II clinical trial SPEARHEAD-1 in 137 adult and pediatric patients with unresectable or metastatic synovial sarcoma who had received prior systemic therapy and whose tumors expressed MAGE-A4.

Overall response rate was 43.8%, including a complete response rate of 3.6%. The median duration of response was 5.3 months. Among patients whose disease responded to afami-cel treatment, 31.9% experienced responses that lasted for 24 months or longer.

The prescribing information for afami-cel includes a boxed warning for cytokine release syndrome, a potentially life-threatening inflammatory response caused by the rapid activation of immune cells and the release of large amounts of inflammatory molecules.

Afami-cel is administered as a single infusion containing 1.62×109 to 10×109 MAGE-A4-TCR-positive T cells.

Synovial sarcoma is a rare and aggressive cancer that accounts for 5% to 10% of soft tissue sarcomas. It is most common among young adults and adolescents and occurs frequently in the extremities. According to federal statistics, it was estimated that 13,910 individuals would be diagnosed with a soft tissue cancer and 5,400 patients would die of the disease in 2026 in the United States. 

The FDA rendered its decision on June 22, 2026. Check this resource for updated information on all therapeutics regulated by the FDA.